Home Cart Sign in  
Chemical Structure| 22494-42-4 Chemical Structure| 22494-42-4
Chemical Structure| 22494-42-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Diflunisal is a difluorophenyl derivate of salicylic acid and a nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic and anti-inflammatory properties. The mechanism of action of diflunisal is as a cyclooxygenase Inhibitor.

Synonyms: MK-647; 5-(2,4-Difluorophenyl)salicylic Acid; Dflunisal

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Diflunisal

CAS No. :22494-42-4
Formula : C13H8F2O3
M.W : 250.20
SMILES Code : O=C(C1=CC(C2=CC=C(F)C=C2F)=CC=C1O)O
Synonyms :
MK-647; 5-(2,4-Difluorophenyl)salicylic Acid; Dflunisal
MDL No. :MFCD00057834

Safety of Diflunisal

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335-H351-H361
Precautionary Statements:P261-P305+P351+P338

Application In Synthesis of Diflunisal

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 22494-42-4 ]

[ 22494-42-4 ] Synthesis Path-Downstream   1~3

  • 1
  • [ 22494-42-4 ]
  • [ 14252-80-3 ]
  • bupivacaine diflunisal salt [ No CAS ]
YieldReaction ConditionsOperation in experiment
With alkaly hydroxide or an strong acid solution; In water;pH 5 - 7;Acidic conditions; The compound in Example 1 was also prepared by dissolving an amount of <strong>[14252-80-3]<strong>[14252-80-3]bupivacaine</strong> hydrochloride</strong> in water. This solution was added to an aqueous solution (pH 8.0) containing an eqiumolar amount of diflunisal. After mixing the pH of the reaction mixture was adjusted to pH 5-7 by using a suitable alkali hydroxide or an strong acid solution. The precipitated salt was isolated and recrystallized as described in Examples 1and 2.
  • 2
  • [ 22494-42-4 ]
  • [ 89365-50-4 ]
  • 4-hydroxy-alpha1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol-5-(2,4-difluorophenyl)salicylic acid salt [ No CAS ]
  • 3
  • [ 3081-61-6 ]
  • [ 22494-42-4 ]
  • L-theanine diflunisal cocrystal [ No CAS ]
YieldReaction ConditionsOperation in experiment
In water; isopropyl alcohol; 0.373 g of diflunisal (1 .491 mmol) and 0.269 g of L-<strong>[3081-61-6]theanine</strong> (1 .544 mmol) were weighed directly into the bowl of an agate mortar, and wetted with 70% isopropanol to form a moderately thick slurry. The slurry was thoroughly ground at the time of mixing, and then periodically re-ground until the contents were dry. The XRPD pattern of the product is shown in Figure 10a, while the FTIR spectrum is shown in Figure 10b. The DSC melting endotherm of the product was characterized by a peak maximum at 172C.
 

Historical Records

Categories